CAN:s bibliotek

*000      am
*00113576
*008070120|2004|||||||||||e||||||||||0|eng|d
*020  $a0-309-09128-4$x0-309-09128-4
*24510$aNew treatments for addiction :$bbehavioral, ethical, legal and social questions
*260  $aWashington, DC :$bNational Academy Press,$c2004$y2004
*300  $a306 s :$bill.
*520  $aIntroduction and background. Clinical trials. Treatment, financing, and costs. Behavioral responses and consent. Appendixes. Vaccines and depot medications for drug addiction: rationale, mechanisms of action, treatment implications. What will we learn from the FDA clinical trials process and what will we still want to know about immunotherapies and depot medications to treat drug dependence? Putting addiction treatment medications to use: lessons learned. Adoption of drug abuse treatment technology in specialty and primary care settings. The use of immunotherapies and sustained-release formulations in the treatment and drug addiction: will current law support coercion? Ethical issues in immunotherapies and depot medications for substance abuse. Costs and benefits of immunotherapies or depot medications for the treatment of drug abuse. Anticipating unintended consequences of vaccine-like immunotherapies and depot medications for addictive drug use. Vaccines and immunotherapies to control addiction in minors: the legal framework. Biographical sketches of committee members and staff. (From the table of contents)
*650 4$aEthics
*650 4$aLegislation and jurisprudence
*650 4$aPsychology
*650 4$aSubstance-related disorders
*650 4$aRehabilitation
*650 4$aDrug therapy
*650 4$aDelayed-action preparations
*653  $aFarmakoterapi
*653  $aImmunterapi
*653  $aEtik
*653  $aBehandling
*7001 $aHarwood, Henrik J.$eed.
*7001 $aMyers, Tracy G.$eed.
*7101 $aNational Academies (Förenta staterna). Committee on
*7101 $aImmunotherapies and Sustained-Release Formulations for
*7101 $aTreating Drug Addiction.
*852  $h5b225
^